7526 Background: Dietary supplement usage is prevalent among cancer patients in the United States (US), estimated at 70% (Du et al., 2020). For patients with plasma cell disorders (PCDs), there is a strong interest in supplement use. Our 23-question survey aims to understand the perceptions, habits, and knowledge surrounding specific supplements — Vitamin D, omega-3 fatty acids, turmeric/curcumin, and probiotics. Methods: From September 2023 to January 2024, 480 survey responses were collected via HealthTree Cure Hub. Deidentified demographic and survey data were retrieved, and summary statistics were used to evaluate responses. Results: Survey participants were predominantly female (58%), white (78%), aged ≥65 (61%), with a college degree or above (67%), and from the US (90%). While most patients (71%) used supplements pre-diagnosis, there was a 46% increase in supplement use post-diagnosis, where95% used supplements. Most patients obtained supplement information online — including medical media (45%) and myeloma education websites (28%)— and from physicians, such as oncologists (46%) or primary care providers (34%). Patient’s goals for supplement use included immune support (70%), prevention of nutritional deficiencies (54%), or halting cancer progression (38%). Of patients, 63% discussed their supplement use with their physician, with 74% preferring their oncologist’s recommendations. Overall, 91% of patients expressed interest in research on the risks and benefits of supplement use. Conclusions: This survey underscores the unmet need for research on supplements. Despite limited evidence, most survey participants reported an increase in supplement use after being diagnosed with a PCD, primarily interested in their oncologist's recommendations. [Table: see text]